Merck & Co Inc (XBUL:6MK)
лв 97.9 0 (0%) Market Cap: 475.39 Bil Enterprise Value: 520.01 Bil PE Ratio: 20.83 PB Ratio: 5.65 GF Score: 87/100

Merck & Co Inc at Citi BioPharma Conference Transcript

Sep 06, 2023 / 05:50PM GMT
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

So delighted to introduce our next speaker, Dr. Marjorie Green at Merck, who heads Oncology Development. Marjorie came 5 months ago from Seagen. We're also joined by representatives of Merck's IR team.

I'm going to give opportunities for those of you in the audience to ask questions throughout the day. So just raise your hand if you would like me to put a question to Marjorie, and we can kind of go from there.

Maybe we start with TIGIT, or TIGIT, as Roger used to like referring it. I like TIGIT because it rhymes with the title of the first report we wrote about it. TIGIT, we totally dig it. And on that note, Roche inversely disclosed their Phase II data, which is a whole another story.

But it's quite informative, and you obviously, did biostatistical analysis, trying to assess the probability of hitting, depending on what you assume for the alpha spend was for the PFS region and what you think the hazard ratio is going to be for the remaining patients. It's not complicated stuff.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot